UPEXI, INC. current report, 13 July 2022

SEC Form 8-K Summary

Registrant: Grove, Inc. (filing metadata identifies UPEXI, Inc.; the provided filing names Grove, Inc.)
Report date: July 13, 2022; signed July 14, 2022
Filing items: Regulation FD Disclosure, Other Events, and Exhibits

Business Context and Reporting Period

The filing reports the issuance of a press release containing a letter to shareholders from Chief Executive Officer Allan Marshall. It is not a periodic financial results filing and does not cover a defined quarterly or annual reporting period.

Financial and Operating Metrics

  • The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, or other quantitative financial metrics.
  • No financial statements or operating forecasts are included in the provided text.

Material Changes Versus Prior Period

No comparable-period financial or operating information is provided. The filing only discloses the issuance of the CEO’s shareholder letter and related press release.

Guidance, Outlook, Risks, and Unusual Items

  • The filing contains general cautionary language regarding forward-looking statements, including risks related to assumptions, growth strategy, financial results, product development, market acceptance, and industry data.
  • The substantive contents of Exhibit 99.1, including management’s shareholder letter and any specific outlook or guidance, are not included in the provided filing text.
  • Items 7.01 and 8.01 information, including Exhibit 99.1, was furnished and generally was not deemed filed or incorporated by reference under the Securities Exchange Act or Securities Act.

Investor Verification Checklist

  • Verify the registrant identity, because the request metadata identifies UPEXI, Inc., while the filing identifies Grove, Inc.
  • Review Exhibit 99.1 for the CEO’s specific statements, strategy, guidance, and any financial or operating claims.
  • Confirm whether the shareholder letter contains material developments not summarized in the Form 8-K body.
  • Assess the stated forward-looking risks and the limitations applicable to furnished, rather than filed, information.